gemcitabine has been researched along with panobinostat in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (25.00) | 29.6817 |
| 2010's | 5 (62.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Bluethner, T; Caca, K; Moebius, C; Mossner, J; Niederhagen, M; Serr, F; Wiedmann, M; Witzigmann, H | 1 |
| Bluethner, T; Caca, K; Haefner, M; Moebius, C; Mossner, J; Niederhagen, M; Wiedmann, M; Wittekind, C | 1 |
| Bendell, JC; Burris, HA; Greco, FA; Infante, JR; Jones, SF; Murphy, PB; Spigel, DR; Thompson, DS; Yardley, DA | 1 |
| Cao, Q; Dudek, AZ; Wang, H | 1 |
| Budman, DR; Calabro, A; Lesser, M; Rosen, L | 1 |
| Bessler, M; Engert, A; Hansen, HP; Henke, A; Klein, JM; Reiners, KS; Sauer, M; von Strandmann, EP | 1 |
| Andersson, BS; Brammer, JE; Champlin, RE; Hosing, C; Ji, J; Li, Y; Liu, Y; Nieto, Y; Teo, EC; Valdez, BC | 1 |
| Andersson, BS; Bashir, Q; Li, Y; Liu, Y; Murray, D; Nieto, Y; Qazilbash, MH; Valdez, BC | 1 |
2 trial(s) available for gemcitabine and panobinostat
| Article | Year |
|---|---|
A phase I study of panobinostat in combination with gemcitabine in the treatment of solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Female; Gemcitabine; Humans; Hydroxamic Acids; Indoles; Male; Middle Aged; Neoplasms; Panobinostat; Treatment Outcome | 2011 |
Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Disease Progression; Disease-Free Survival; Female; Gemcitabine; Humans; Hydroxamic Acids; Indoles; Male; Middle Aged; Pancreatic Neoplasms; Panobinostat; Pyrazines | 2012 |
6 other study(ies) available for gemcitabine and panobinostat
| Article | Year |
|---|---|
Inhibition of histone deacetylase for the treatment of biliary tract cancer: a new effective pharmacological approach.
Topics: Animals; Apoptosis; Biliary Tract Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Therapy, Combination; Enzyme Inhibitors; Gemcitabine; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Mice; Mice, Nude; Panobinostat; Xenograft Model Antitumor Assays | 2007 |
Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p21; Deoxycytidine; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Gemcitabine; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Hydroxamic Acids; Immunoblotting; Immunohistochemistry; In Situ Nick-End Labeling; Indoles; Ki-67 Antigen; Mice; Mice, Nude; Pancreatic Neoplasms; Panobinostat; Time Factors | 2008 |
Identification of unique synergistic drug combinations associated with downexpression of survivin in a preclinical breast cancer model system.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Caspase 3; Cell Line, Tumor; Deoxycytidine; Docetaxel; Down-Regulation; Doxorubicin; Drug Screening Assays, Antitumor; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemcitabine; Humans; Hydroxamic Acids; Indoles; Inhibitor of Apoptosis Proteins; Panobinostat; Receptor, ErbB-2; Survivin; Taxoids | 2012 |
The histone deacetylase inhibitor LBH589 (panobinostat) modulates the crosstalk of lymphocytes with Hodgkin lymphoma cell lines.
Topics: Apoptosis; Blotting, Western; Brentuximab Vedotin; Cell Line, Tumor; Cells, Cultured; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gemcitabine; Histone Deacetylase Inhibitors; Hodgkin Disease; Humans; Hydroxamic Acids; Immunoconjugates; Indoles; Interferon-gamma; Ki-1 Antigen; Lymphocytes; Microscopy, Fluorescence; Panobinostat; Reverse Transcriptase Polymerase Chain Reaction; Tumor Necrosis Factor-alpha | 2013 |
Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells.
Topics: Adult; Antineoplastic Agents; Apoptosis; Bortezomib; Busulfan; Cell Line, Tumor; Cell Survival; Chromatin Assembly and Disassembly; Deoxycytidine; DNA Damage; Dose-Response Relationship, Drug; Drug Synergism; Gemcitabine; Humans; Hydroxamic Acids; Indoles; Male; Melphalan; Membrane Potential, Mitochondrial; Middle Aged; Panobinostat; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Reactive Oxygen Species; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2016 |
Panobinostat and venetoclax enhance the cytotoxicity of gemcitabine, busulfan, and melphalan in multiple myeloma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Busulfan; Cell Line, Tumor; Cytotoxins; Deoxycytidine; DNA Fragmentation; Drug Screening Assays, Antitumor; Endoplasmic Reticulum Chaperone BiP; Endoplasmic Reticulum Stress; Gemcitabine; Humans; Melphalan; Membrane Potential, Mitochondrial; Multiple Myeloma; Neoplasm Proteins; Panobinostat; Signal Transduction; Sulfonamides | 2020 |